Viola Chen

Viola Chen

Company: Merck

Job title: Senior Medical Director, Oncology

Seminars:

ROR1 Targeting with the Antibody Drug-Conjugate MK-2140 in Aggressive Non-Hodgkins Lymphoma 5:00 pm

Discussing how Receptor tyrosine kinase-like orphan receptor 1 (ROR1) represents an attractive, cancer-specific, cellsurface target for antibody-based therapies MK-2140 is a novel antibody-drug conjugate (ADC) that binds to an external ROR1 epitope and rapidly internalizes to deliver monomethyl auristatin E (MMAE) to tumor cells Evaluating how this Phase 1 dose-ranging study provides the first clinical…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.